<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01052038</url>
  </required_header>
  <id_info>
    <org_study_id>STU00018901</org_study_id>
    <nct_id>NCT01052038</nct_id>
  </id_info>
  <brief_title>Post Operative Sore Throat and Dexamethasone</brief_title>
  <official_title>The Effect of Systemic Prophylactic Dexamethasone on the Incidence of Postoperative Sore Throat in Patients Undergoing Ambulatory Laparoscopic Gynecologic Surgery: A Prospective, Randomized, Double Blinded, Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sore throat is a common postoperative complaint that can lead to morbidity and patient
      dissatisfaction . The incidence of sore throat has been reported to be between 6% and 90%
      even under optimal intubating conditions. There are several factors that have been shown to
      contribute to postoperative sore throat such as patient related factors, type of anesthesia
      and type of surgery.

      Corticosteroids are also commonly used in the perioperative period to potentiate analgesics
      and as antiemetics. The preoperative administration of dexamethasone can decrease the
      incidence and severity of postoperative sore throat which is rated by patients as one of the
      most undesirable outcomes in the postoperative period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sore throat is a common postoperative complaint that can lead to morbidity and patient
      dissatisfaction. The incidence of sore throat has been reported to be between 6% and 90% even
      under optimal intubating conditions. There are several factors that have been shown to
      contribute to postoperative sore throat such as patient related factors, type of anesthesia
      and type of surgery. It has been observed that gargle with azunol reduced the incidence of
      postoperative sore throat from 65% to 25 %. Similarly, a reduction in sore throat following
      tracheal intubation from 78% to 40 % has been reported after gargle with ketamine performed 5
      minutes before induction of anesthesia. More recently, it was also demonstrated that
      preoperative gargle with licorice resulted in a 57 percent reduction of the absolute risk of
      sore throat after intubation. Although the gargling technique has been shown to be successful
      in decreasing the incidence of postoperative sore throat, it has a limited feasibility
      because the volumes administered could increase the chance of aspiration if ingested and it
      may be difficult to perform in sedated patients and in children.

      Tracheal intubation is associated with an increase of polymorphonuclear cells in the tracheal
      tissue and plasma levels of interleukin 6, suggesting an inflammatory response to the
      presence of the endotracheal tube itself or to some aspect of the intubation process.
      Dexamethasone is widely prescribed for the treatment of a sore throat resulting from tracheal
      mechanical irritation due to its modulating effects of tissue edema and pain. Moreover,
      prophylactic dexamethasone has been shown to be effective in reducing the frequency of airway
      obstruction in patients at high risk for laryngeal edema following extubation. It decreases
      postoperative sore throat in patients requiring double-lumen tubes.

      Dexamethasone has been shown to decrease postoperative sore throat in patients requiring
      hospital admission but it has not been evaluated in the ambulatory setting. Ambulatory
      patients usually need to return to work faster than patients who are admitted to the
      hospital. Their ability to tolerate fluids and food might help them to return to normal
      living. They also have smaller surgeries which might increased their perception to sore
      throat pain when compared to bigger, more painful procedures.

      Possible side effects of corticosteroids such as retardation of wound healing, susceptibility
      to infection and gastrointestinal hemorrhage have not been noted with short term use (&lt;24
      hours ) in surgical patients. Corticosteroids are also commonly used in the perioperative
      period to potentiate analgesics and as antiemetics.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjects Assessment of Sore Throat Pain at 24 Hours</measure>
    <time_frame>24 hours</time_frame>
    <description>The reported score for sore throat on a 1 to 5 scale where 1 is a severe sore throat and 5 is no sore throat. This evaluation was made by investigator initiated phone conversation at 24 hours following surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Recovery at 24 Hours</measure>
    <time_frame>24 hours</time_frame>
    <description>The quality of recovery (QoR-40) questionnaire assess the subjects perceived quality of recovery following surgery. The tool assess pain, physical and psychological well being as well as ability to ability for self-care. Questions are scored on a 1 to 5 point scale with a higher value indication a better outcome. The scores or the individual questions are summed to obtain a total score. The minimum total score is 30 and the maximum is 200. The higher the score the better the recovery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Sore Throat at 3 Hours Post Surgery.</measure>
    <time_frame>3 hours.</time_frame>
    <description>Subjects were asked at 3 hours post surgery if they were experiencing a sore throat.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid Consumption at 24 Hours</measure>
    <time_frame>24 hours</time_frame>
    <description>The cumulative use of an opioid analgesic pain medication taken during the first 24 hours for pain and discomfort. Data reported as equivalent dose of oral morphine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hoarseness at 24 Hours</measure>
    <time_frame>24 hours</time_frame>
    <description>Self assessment of the degree of hoarseness 24 hours after surgery and intratracheal intubation on a 1 to 1 Likert scale. 0 = no hoarseness and 3= hoarseness easily noted at time of interview.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Sore Throat</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Group 1 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline 100ml (placebo) administered as a intravenous infusion 30 minutes prior to surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Dexamethasone 0.05mg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexamethasone 0.05 mg/kg administered in 100 ml of sterile saline solution prior to surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3:Dexamethasone 0.1mg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexamethasone 0.1mg/kg administered in 100ml of sterile saline solution prior to surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo administration</intervention_name>
    <description>Placebo administration</description>
    <arm_group_label>Group 1 Placebo</arm_group_label>
    <other_name>Decadron</other_name>
    <other_name>Corticosteroid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone 0.05mg/kr administration</intervention_name>
    <description>Dexamethasone 0.05mg/kr administered in 100ml of sterile saline solution prior to the start of surgery.</description>
    <arm_group_label>Group 2: Dexamethasone 0.05mg/kg</arm_group_label>
    <other_name>Decadron</other_name>
    <other_name>corticosteroid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone 0.1mg/kg</intervention_name>
    <description>Dexamethasone 0.1mg/kg administered in 100ml of sterile saline solution prior to the beginning of surgery.</description>
    <arm_group_label>Group 3:Dexamethasone 0.1mg/kg</arm_group_label>
    <other_name>Decadron</other_name>
    <other_name>corticosteroid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients undergoing outpatient laparoscopic gynecologic surgery

          -  ASA PS I and II

          -  Age between 18 and 64 years

          -  Fluent in English

        Exclusion Criteria:

          -  History of recent respiratory tract infection

          -  Pregnancy, breastfeeding

          -  Current treatment with analgesics

          -  Current use of corticosteroids

          -  Anticipated difficult intubation

          -  Risk factors for post-operative aspiration
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gildasio DeOliveira, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwesten University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>De Oliveira GS Jr, Ahmad S, Fitzgerald PC, Marcus RJ, Altman CS, Panjwani AS, McCarthy RJ. Dose ranging study on the effect of preoperative dexamethasone on postoperative quality of recovery and opioid consumption after ambulatory gynaecological surgery. Br J Anaesth. 2011 Sep;107(3):362-71. doi: 10.1093/bja/aer156. Epub 2011 Jun 13.</citation>
    <PMID>21669954</PMID>
  </results_reference>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2010</study_first_submitted>
  <study_first_submitted_qc>January 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2010</study_first_posted>
  <results_first_submitted>October 31, 2011</results_first_submitted>
  <results_first_submitted_qc>April 5, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 2, 2012</results_first_posted>
  <last_update_submitted>April 5, 2012</last_update_submitted>
  <last_update_submitted_qc>April 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Gildasio De Oliveira</investigator_full_name>
    <investigator_title>Gildasio De Oliveira, M.D. Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Sore throat</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharyngitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>ASA physical status I and II females undergoing outpatient gynaecological laparoscopy. Patients with a history of recent respiratory tract infection (&lt;1 month), current use of an opioid analgesic or corticosteroid, pregnancy, or anticipated difficult airways were not enrolled. Subjects were enrolled between January 2010 thru September 2010.</recruitment_details>
      <pre_assignment_details>No subjects were lost or excluded after consent was signed and prior to allocation.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1 Placebo</title>
          <description>Normal saline 100ml (placebo) administered as a intravenous infusion 30 minutes prior to surgery.</description>
        </group>
        <group group_id="P2">
          <title>Group 2: Dexamethasone 0.05mg/kg</title>
          <description>Dexamethasone 0.05 mg/kg administered in 100 ml of sterile saline solution prior to surgery</description>
        </group>
        <group group_id="P3">
          <title>Group 3:Dexamethasone 0.1mg/kg</title>
          <description>Dexamethasone 0.1mg/kg administered in 100ml of sterile saline solution prior to surgery.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1 Placebo</title>
          <description>Normal saline 100ml (placebo) administered as a intravenous infusion 30 minutes prior to surgery.</description>
        </group>
        <group group_id="B2">
          <title>Group 2: Dexamethasone 0.05mg/kg</title>
          <description>Dexamethasone 0.05 mg/kg administered in 100 ml of sterile saline solution prior to surgery</description>
        </group>
        <group group_id="B3">
          <title>Group 3:Dexamethasone 0.1mg/kg</title>
          <description>Dexamethasone 0.1mg/kg administered in 100ml of sterile saline solution prior to surgery.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="40"/>
            <count group_id="B4" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36" spread="11"/>
                    <measurement group_id="B2" value="36" spread="7"/>
                    <measurement group_id="B3" value="39" spread="11"/>
                    <measurement group_id="B4" value="37" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subjects Assessment of Sore Throat Pain at 24 Hours</title>
        <description>The reported score for sore throat on a 1 to 5 scale where 1 is a severe sore throat and 5 is no sore throat. This evaluation was made by investigator initiated phone conversation at 24 hours following surgery.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Placebo</title>
            <description>Normal saline 100ml (placebo) administered as a intravenous infusion 30 minutes prior to surgery.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Dexamethasone 0.05mg/kg</title>
            <description>Dexamethasone 0.05 mg/kg administered in 100 ml of sterile saline solution prior to surgery</description>
          </group>
          <group group_id="O3">
            <title>Group 3:Dexamethasone 0.1mg/kg</title>
            <description>Dexamethasone 0.1mg/kg administered in 100ml of sterile saline solution prior to surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects Assessment of Sore Throat Pain at 24 Hours</title>
          <description>The reported score for sore throat on a 1 to 5 scale where 1 is a severe sore throat and 5 is no sore throat. This evaluation was made by investigator initiated phone conversation at 24 hours following surgery.</description>
          <units>units on a scale (1 to 5)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3" upper_limit="5"/>
                    <measurement group_id="O2" value="4" lower_limit="3" upper_limit="5"/>
                    <measurement group_id="O3" value="5" lower_limit="4" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Recovery at 24 Hours</title>
        <description>The quality of recovery (QoR-40) questionnaire assess the subjects perceived quality of recovery following surgery. The tool assess pain, physical and psychological well being as well as ability to ability for self-care. Questions are scored on a 1 to 5 point scale with a higher value indication a better outcome. The scores or the individual questions are summed to obtain a total score. The minimum total score is 30 and the maximum is 200. The higher the score the better the recovery</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Placebo</title>
            <description>Normal saline 100ml (placebo) administered as a intravenous infusion 30 minutes prior to surgery.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Dexamethasone 0.05mg/kg</title>
            <description>Dexamethasone 0.05 mg/kg administered in 100 ml of sterile saline solution prior to surgery</description>
          </group>
          <group group_id="O3">
            <title>Group 3:Dexamethasone 0.1mg/kg</title>
            <description>Dexamethasone 0.1mg/kg administered in 100ml of sterile saline solution prior to surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Recovery at 24 Hours</title>
          <description>The quality of recovery (QoR-40) questionnaire assess the subjects perceived quality of recovery following surgery. The tool assess pain, physical and psychological well being as well as ability to ability for self-care. Questions are scored on a 1 to 5 point scale with a higher value indication a better outcome. The scores or the individual questions are summed to obtain a total score. The minimum total score is 30 and the maximum is 200. The higher the score the better the recovery</description>
          <units>units on a scale (30 to 200) higher scod</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171" lower_limit="160" upper_limit="182"/>
                    <measurement group_id="O2" value="179" lower_limit="175" upper_limit="185"/>
                    <measurement group_id="O3" value="193" lower_limit="192" upper_limit="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Kruskal-Wallis</method>
            <method_desc>Dunn's post hoc-test corrected for 12 comparisons.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>14</ci_lower_limit>
            <ci_upper_limit>29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7</ci_lower_limit>
            <ci_upper_limit>22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Sore Throat at 3 Hours Post Surgery.</title>
        <description>Subjects were asked at 3 hours post surgery if they were experiencing a sore throat.</description>
        <time_frame>3 hours.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Placebo</title>
            <description>Normal saline 100ml (placebo) administered as a intravenous infusion 30 minutes prior to surgery.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Dexamethasone 0.05mg/kg</title>
            <description>Dexamethasone 0.05 mg/kg administered in 100 ml of sterile saline solution prior to surgery</description>
          </group>
          <group group_id="O3">
            <title>Group 3:Dexamethasone 0.1mg/kg</title>
            <description>Dexamethasone 0.1mg/kg administered in 100ml of sterile saline solution prior to surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Sore Throat at 3 Hours Post Surgery.</title>
          <description>Subjects were asked at 3 hours post surgery if they were experiencing a sore throat.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opioid Consumption at 24 Hours</title>
        <description>The cumulative use of an opioid analgesic pain medication taken during the first 24 hours for pain and discomfort. Data reported as equivalent dose of oral morphine.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Placebo</title>
            <description>Normal saline 100ml (placebo) administered as a intravenous infusion 30 minutes prior to surgery.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Dexamethasone 0.05mg/kg</title>
            <description>Dexamethasone 0.05 mg/kg administered in 100 ml of sterile saline solution prior to surgery</description>
          </group>
          <group group_id="O3">
            <title>Group 3:Dexamethasone 0.1mg/kg</title>
            <description>Dexamethasone 0.1mg/kg administered in 100ml of sterile saline solution prior to surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Opioid Consumption at 24 Hours</title>
          <description>The cumulative use of an opioid analgesic pain medication taken during the first 24 hours for pain and discomfort. Data reported as equivalent dose of oral morphine.</description>
          <units>mg of oral morphine equivalents</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="20" upper_limit="30"/>
                    <measurement group_id="O2" value="20" lower_limit="10" upper_limit="32.5"/>
                    <measurement group_id="O3" value="10" lower_limit="10" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Kruskal-Wallis</method>
            <method_desc>Post hoc test using Dunn's test corrected for 12 comparisons</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>10</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hoarseness at 24 Hours</title>
        <description>Self assessment of the degree of hoarseness 24 hours after surgery and intratracheal intubation on a 1 to 1 Likert scale. 0 = no hoarseness and 3= hoarseness easily noted at time of interview.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Placebo</title>
            <description>Normal saline 100ml (placebo) administered as a intravenous infusion 30 minutes prior to surgery.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Dexamethasone 0.05mg/kg</title>
            <description>Dexamethasone 0.05 mg/kg administered in 100 ml of sterile saline solution prior to surgery</description>
          </group>
          <group group_id="O3">
            <title>Group 3:Dexamethasone 0.1mg/kg</title>
            <description>Dexamethasone 0.1mg/kg administered in 100ml of sterile saline solution prior to surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Hoarseness at 24 Hours</title>
          <description>Self assessment of the degree of hoarseness 24 hours after surgery and intratracheal intubation on a 1 to 1 Likert scale. 0 = no hoarseness and 3= hoarseness easily noted at time of interview.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No hoarseness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No hoarseness at interview but present during 24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hoarseness at interview noted by patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hoarseness easily noted by interviewer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for 24 hours following surgery</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1 Placebo</title>
          <description>Normal saline 100ml (placebo) administered as a intravenous infusion 30 minutes prior to surgery.</description>
        </group>
        <group group_id="E2">
          <title>Group 2: Dexamethasone 0.05mg/kg</title>
          <description>Dexamethasone 0.05 mg/kg administered in 100 ml of sterile saline solution prior to surgery</description>
        </group>
        <group group_id="E3">
          <title>Group 3:Dexamethasone 0.1mg/kg</title>
          <description>Dexamethasone 0.1mg/kg administered in 100ml of sterile saline solution prior to surgery.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>SNOMED CT</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hoarseness</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="40"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Coughing</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="40"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="40"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was limited to 2 doses of dexamethasone and was underpowered to assess side effects such as hyperglycemia or delayed wound healing. Study was limited to a single type of surgery and results may differ in different types of surgery.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Robert J. McCarthy</name_or_title>
      <organization>Northwestern University Feinberg School of Medicine</organization>
      <phone>312-926-9015</phone>
      <email>r-mccarthy@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

